This page contains a Flash digital edition of a book.
annual conference.

Regener8’s Annual Conference 2011

Delivery of Regenerative Technologies on a Commercial Scale

Thursday 29 September 2011 Lowry Theatre and Art Gallery, Salford Quays, Manchester

Some of the UK’s leading experts in the field of regenerative medicine will share best practise on how to commercialise regenerative therapies at the Regener8 Annual Conference 2011.

David Haddow

The conference, aimed at academics, clinicians and industry representatives who operate in the field of translational regenerative medicine will feature some of the leading RegenMed experts in the UK.

Keynote speakers will include: Cathy Prescott

• David Haddow, Operations Director, Altrika Ltd – ‘The development and production of biomaterials and advanced surfaces for regenerative therapies’

• Cathy Prescott, Biolatris Ltd and Chair, UK Stem Cell and Regenerative Medicine Networks – ‘Who benefits, who pays; who should finance the RegenMed sector?’

Angela Scott

• Angela Scott, Director of Operations, Angel Biotechnology – ‘Manufacturing cells for cell-based regenerative therapies – from an Angel’s perspective’

• David Williams, Director of the Research School of Health and Life Sciences, Loughborough University – ‘The manufacture of cell-seeded devices and cells for regenerative therapies’

Dr David Haddow, Operations Director of Altrika, has 10 years commercial experience in the cell therapy sector. He comments:

“ I think it is great that an organisation such as Regener8 is bringing together the different disciplines and people involved in regenerative medicine, so we can discuss ways of working together in order to bring regenerative therapies to the clinic more quickly. At the conference, I will be talking about the development and production of biomaterials and advanced surfaces for regenerative therapies, speaking from my experience and also hope to open discussion on the subject. There is a wealth of expertise in the UK; the key is tapping into this and collaboration between academia, industry and the NHS.”

John Fisher Director of regeNer8 comments:

“ Our annual conference features key note speakers from some of the key RegenMed organisations in the UK. Their experience of commercialising RegenMed is invaluable to other companies and researchers wishing to bring their therapies to market. Regener8 is focused on encouraging collaboration and some of our funded projects which feature collaborations between industry and academia will be showcased on the day, with those who led the project sharing their experiences.”

David Williams

As well as this there will be key academic, clinical and industry speakers from the regenerative medicine community in the UK. Other presentations will include those being made by representatives of completed Regener8 funded projects.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36